美國

證券和交易所委員會

華盛頓特區20549

表格 6-K

外國私人控制者根據規則13a-16提出的報告

或者根據1934年證券交易法第15d-16條

截至九月份2024

委員會文件號碼:001-36582

Altamira Therapeutics有限公司

（註冊機構的確切名稱，如其憲章所規定）

克拉倫登大廈,

2號教堂街

百慕大HM11，漢密爾頓

(總部 行政辦公地址)

在標記處打勾，表示登記人是否會以20-F或40-F表格爲封套提交年度報告:

表格 20-F ☒ 表格40-F ☐

引用公司文件

Exhibits 99.1 and 99.2 to this Report on Form 6-k shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers 333-249347, 333-261127, 333-264298, 333-267584, 333-272338和333-276427) and Form S-8 (Registration Numbers 333-232735, 333-252141和333-278595) of Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit 99.3 to this Report on Form 6-k shall not be deemed 「filed」 for purposes of Section 18 of the Securities Exchange Act of 1934 (the 「Exchange Act」) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

簽名

New Gold Inc. /s/ Sean Keating Sean Keating 副總裁，總法律顧問和公司秘書爲公司提供企業活動更新（除非另有說明，否則所有數字均以美元計）。

附件描述

3